Stock Price & Analysis

Sell CGON stock as it shows a slight decline in regular market performance. Consider holding or monitoring for further market movements.

Price Prediction for CGON Stock in 2025

CGON stock is expected to reach $35 by the end of 2025. This prediction is based on the stock entering oversold territory with an RSI of 28.3, indicating potential exhaustion of selling pressure and possible buying opportunities. Analysts maintain a Buy rating with a price target of $65.00, suggesting strong confidence in the stock's recovery.

The S1 support level for CGON Stock is $25.78 ,The R1 resistant level for CGON Stock is $28.47.

As of the end of day on 2025-03-24, the price of CGON Stock was $28.28.

The target price for CGON Stock according to analyst rating is 74.33, with the highest price target at 83.00 and the lowest at 65.00. Analysts have a Strong Buy rating on CGON Stock overall.

The market cap of CGON is $2.0B.

CGON is trading near its 52-week low of $25.23, with an RSI of 28.3, indicating oversold conditions and potential undervaluation. Despite this, the company reported a quarterly GAAP net loss of $20.41 million, raising concerns about profitability. Analysts maintain a Strong Buy rating with a $68.80 average target, suggesting long-term upside. However, negative insider sentiment and poor financial performance indicate risks. CGON appears undervalued technically but fundamentally challenged.

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Price Prediction for CGON Stock by 2030

CGON stock is predicted to reach $65 by 2030, driven by its oversold condition and potential rebound. The stock is currently trading at $25.23, near its 52-week low, with an RSI of 28.3, indicating exhaustion of selling pressure. Analysts have a consensus target of $68.80, with a Buy rating, supporting long-term growth.

CGON has a total of 61 employees.